Evidence map›Paper›PMID 37445385›Full record

ArticleJournal of clinical medicine2023

Safety and Tolerability of tDCS across Different Ages, Sexes, Diagnoses, and Amperages: A Randomized Double-Blind Controlled Study.

Derrick M Buchanan, Sarah Amare, Genevieve Gaumond, Amedeo D'Angiulli, Philippe Robaey

Registry-linked trialAbstract read
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06368726 (Results of the Application of 80 Sessions of tDCS for 12 Months in Children Between 6 and 11 Years Old With Autism Spectrum Disorder With Rare Diseases, Genetic Problems or PANDAS), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06368726 phase1enrolling by invitationnot on this mapstarted 2024, after this paper: background citation

Results of the Application of 80 Sessions of tDCS for 12 Months in Children Between 6 and 11 Years Old With Autism Spectrum Disorder With Rare Diseases, Genetic Problems or PANDAS

TypeinterventionalSponsorSpanish Foundation for Neurometrics DevelopmentRan2024 to 2026Enrolled180ConditionsAttention, Visual Perceptual Weakness, Social Behavior, Fluency DisorderArmstDCS or Transcranial Direct Current Stimulation, Risperidone
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Research progress of tDCS in the treatment of ADHD.Journal of neural transmission (Vienna, Austria : 1996) · 2025
    Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Derrick M BuchananDepartment of Neuroscience, Carleton University, Ottawa, ON K1S 5B6, Canada.ORCID 0000-0003-4478-2844
Sarah AmareDepartment of Neuroscience, Carleton University, Ottawa, ON K1S 5B6, Canada.
Genevieve GaumondDepartment of Neuroscience, Carleton University, Ottawa, ON K1S 5B6, Canada.
Amedeo D'AngiulliDepartment of Neuroscience, Carleton University, Ottawa, ON K1S 5B6, Canada.ORCID 0000-0002-8295-9850
Philippe RobaeyDepartment of Neuroscience, Carleton University, Ottawa, ON K1S 5B6, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique with substantial evidence for its safety and tolerability in adults. However, less than 5% of published tDCS research is in pediatrics. Our primary objective was to investigate tDCS safety, tolerability, and acceptability in a sample of children and adults. We hypothesized that children and adults would be equal with regard to tDCS safety, tolerability, and acceptability. We tested this hypothesis using a Bayesian approach. Sixty participants aged 6-45 (balanced for sex) participated in a randomized double-blind controlled trial. They were randomly assigned to two ten-minute tDCS sessions with varying amperages and electrode locations. The primary outcome measure of this study was the intensity of 13 potential side effects evaluated at six different time points spanning two weeks. Independent sample Bayes factor tests were conducted between children/adults, males/females, clinical/healthy, and low/high amperage groups. As predicted, there was moderate support for the null hypothesis in all between-group analyses. There were no serious adverse events or dropouts, and the number needed to treat for an additional harmful outcome was 23. This study provided evidence supporting the overall short-term safety, tolerability, and acceptability of tDCS including amperages up to 2 mA and different electrode placements.

Indexed as

adolescentschildrensafetytdcstolerability

Identifiers

PMID37445385
PMCPMC10342754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.